+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Personalized Medicine In Oncology"

From
From
From
From
From
From
From
From
From
From
Patient Derived Xenograft (PDX) Models Market Report 2024 - Product Thumbnail Image

Patient Derived Xenograft (PDX) Models Market Report 2024

  • Report
  • September 2024
  • 175 Pages
  • Global
From
From
From
MEK Inhibitors - Global Strategic Business Report - Product Thumbnail Image

MEK Inhibitors - Global Strategic Business Report

  • Report
  • March 2025
  • 132 Pages
  • Global
From
Blood Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Blood Cancer Therapeutics - Global Strategic Business Report

  • Report
  • March 2025
  • 291 Pages
  • Global
From
Loading Indicator

Personalized Medicine in Oncology is a field of medicine that uses genomic information to tailor treatments to individual patients. This approach is based on the idea that each patient's cancer is unique and requires a personalized approach to treatment. Genomics is used to identify the genetic mutations that are driving the cancer, and then treatments are tailored to target those mutations. This approach has the potential to improve outcomes and reduce side effects, as treatments are more targeted and tailored to the individual patient. Companies in the Personalized Medicine in Oncology market include Illumina, Thermo Fisher Scientific, QIAGEN, Agilent Technologies, and PerkinElmer. Show Less Read more